Mr. Francois Roberge reports
LSL PHARMA GROUP PROVIDES UPDATE ON STERI-MED PRODUCTION AND SIGNS AGREEMENTS FOR SEVEN OPHTHALMIC PRODUCTS
LSL Pharma Group Inc. has provided an update on its market opportunities and operations to enhance long-term shareholder value.
Steri-Med expected to resume production
Following the implementation of the key elements of a comprehensive remediation plan approved by Health Canada, Steri-Med's production is expected to resume by the end of November. An earlier inventory buildup enabled an uninterrupted supply to the corporation's clients since the beginning of the fiscal year, including throughout the third quarter. As part of the business strategy, the corporation plans to launch multiple ophthalmic generics in Canada and the United States through 2030.
Adding seven sterile ophthalmic products
As part of the LSL Pharma's pipeline buildout, the corporation signed in-licensing agreements adding seven sterile ophthalmic products to its portfolio. According to Iqvia Canadai, the Canadian market for these seven products represents more than $95-million in annual sales. Commercialization remains subject to obtaining the necessary Health Canada approvals, and the corporation expects to submit the related regulatory filings in the first quarter of 2027. The in-licensing agreements grant exclusive commercialization rights for periods ranging from five to seven years, with renewal options.
"On the eye care side of the business, we are pleased that Steri-Med's commercial production is expected to resume by the end of November, with Health Canada expected to visit shortly to assess our remediation plan's implementation. The comprehensive remediation work completed at the facility will strengthen its quality systems and manufacturing capabilities, providing a stronger foundation for future growth. In addition, we have expanded our portfolio with seven ophthalmic products targeting Canadian market segments with combined annual sales exceeding $95-million. These growth opportunities, combined with the attractive margin profile of our eye care business, position us well for the years ahead," said Francois Roberge, president and chief executive officer.
New private label product for a national customer
To advance strategic growth objectives, LSL MedPlus entered into an agreement with a national customer and expects to begin supplying the private label product in the first quarter of 2027. Based on the framework of the agreement with the customer, this product could make a significant contribution to the private label segment.
"The agreement with a national private label client represents a significant milestone and could create similar opportunities in the future. Following a series of acquisitions that have driven substantial top-line growth, our focus on operational excellence and cross-selling initiatives is beginning to deliver measurable results," concluded Mr. Roberge.
About LSL Pharma Group Inc.
LSL Pharma is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and LSL MedPlus Inc. (formerly Juno OTC Inc.).
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.